Beam Therapeutics (BEAM) Net Income towards Common Stockholders (2019 - 2026)

Beam Therapeutics (BEAM) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$94.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 12.93% year-over-year to -$94.3 million; the TTM figure through Mar 2026 stood at -$65.0 million (up 83.17% YoY), while the FY2025 annual figure was -$80.0 million, up 78.77% from the prior year.
• Net Income towards Common Stockholders slipped to -$94.3 million in Q1 2026 per BEAM's latest filing, from $244.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $244.3 million in Q4 2025 and bottomed at -$112.7 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$57.2 million across 5 years, with a median of -$94.3 million in 2026.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 289.7% — and 2023, when it jumped 472.36%.
• Beam Therapeutics' Net Income towards Common Stockholders stood at -$38.3 million in 2022, then surged by 472.36% to $142.8 million in 2023, then sank by 163.27% to -$90.4 million in 2024, then soared by 370.38% to $244.3 million in 2025, then tumbled by 138.61% to -$94.3 million in 2026.
• Business Quant data shows BEAM's Net Income towards Common Stockholders at -$94.3 million in Q1 2026, $244.3 million in Q4 2025, and -$112.7 million in Q3 2025.